{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-336864","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2026-08-06T12:15:17+00:00","discovered_at":"2026-08-06T12:20:00.284968+00:00","generated_at":"2026-08-06T12:20:09.652604+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Corbus reports Q2 net loss of $35M; cash $117.9M; FDA clearance for CRB-701 registrational study","bullets":["Net loss of $35.0M ($1.81 per share) vs $17.7M ($1.44) in Q2 2025; operating expenses rose to $36.2M including $10M milestone payment.","Cash and investments $117.9M as of June 30, 2026, expected to fund operations into 2028.","FDA cleared TEMPO-1 registrational study (n=250) of CRB-701 in 2L oropharyngeal cancer; enrollment to start September 2026.","CANYON-1 Phase 1b study of CRB-913 in obesity completed last patient visit; topline data expected September 2026.","Appointed new CMO (Dr. Leonardo Viana Nicacio), CBO (Nishant Saxena), and Board member (Brent Pfeiffenberger)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-336864","json":"https://secwatch.observer/filing/0001193125-26-336864.json","markdown":"https://secwatch.observer/filing/0001193125-26-336864.md","text":"https://secwatch.observer/filing/0001193125-26-336864.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000119312526336864/0001193125-26-336864-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000119312526336864/crbp-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T12:20:09.652604+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}